$44.79
▼ -4.5% Today
as of Aug 5, 16:54 ET
Last 30 days
Recent Press Releases & News
Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth ...
SUPN: Lowering target price to $41.00
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
Overview
52-week range
$31
$60
48% of range
Avg surprise (last 3)
+119.5%
Avg reaction (last 2)
+0.6%
100% positive
Latest IV / EM
49%
EM ±8.2% · $47 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $0.45 | $0.14 | +221.4% | +60.7% | +1.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.80 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $0.78 | $0.34 | +129.4% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $0.28 | $0.26 | +7.7% | — | +0.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.69 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.36 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | — | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.29 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.02 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $23M | — | $19M | $17M | $16M | — | $18M | $18M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-8M | — | $-60M | $12M | $-10M | — | $41M | $23M |
| Net income | $-2M | — | $-45M | $22M | $-12M | — | $38M | $20M |
| EPS (diluted) | $-0.04 | — | $-0.80 | $0.40 | $-0.21 | — | $0.69 | $0.36 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $185M | $128M | $151M | $145M | $116M | $69M | $32M | $52M |
| Inventory | $111M | $112M | $107M | $44M | $49M | $54M | $64M | $68M |
| Total current assets | $732M | $644M | $594M | $739M | $688M | $686M | $640M | $591M |
| Total assets | $1.50B | $1.45B | $1.42B | $1.38B | $1.35B | $1.37B | $1.34B | $1.32B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $424M | $391M | $370M | $319M | $317M | $332M | $336M | $358M |
| Total equity | $1.08B | $1.06B | $1.05B | $1.06B | $1.03B | $1.04B | $1.01B | $957M |